UniProt P54756 · PDB · AlphaFold · Substrate: pEY + Mn · Clone: aa 595-1037high-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Dasatinib | 100.0% | 0.0% | 87.97 | 0.699 |
| 2 | Bosutinib | 99.2% | 0.8% | 87.22 | 0.555 |
| 3 | Ponatinib | 98.5% | 1.5% | 78.23 | 0.534 |
| 4 | Repotrectinib | 95.9% | 4.1% | 84.21 | 0.608 |
| 5 | Nilotinib | 93.8% | 6.2% | 96.49 | 0.765 |
| 6 | Cabozantinib | 91.6% | 8.4% | 92.73 | 0.751 |
| 7 | Erdafitinib | 87.6% | 12.4% | 95.71 | 0.737 |
| 8 | Tivozanib | 87.6% | 12.4% | 92.42 | 0.673 |
| 9 | Ripretinib | 87.0% | 13.0% | 92.95 | 0.674 |
| 10 | Crizotinib | 82.1% | 17.9% | 91.39 | 0.581 |
| 11 | Fostamatinib | 77.3% | 22.7% | 96.74 | 0.613 |
| 12 | Vandetanib | 69.4% | 30.6% | 95.74 | 0.723 |
| 13 | Canertinib | 66.1% | 33.9% | 96.49 | 0.671 |
| 14 | Afatinib | 35.9% | 64.1% | 98.50 | 0.709 |
| 15 | Dacomitinib | 33.7% | 66.3% | 97.99 | 0.664 |
| 16 | Gilteritinib | 31.1% | 68.9% | 88.97 | 0.506 |
| 17 | Selpercatinib | 27.6% | 72.4% | 96.72 | 0.635 |
| 18 | Gefitinib | 26.3% | 73.7% | 99.25 | 0.650 |
| 19 | Pralsetinib | 23.8% | 76.2% | 93.43 | 0.643 |
| 20 | Apatinib | 23.4% | 76.6% | 97.73 | 0.704 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 1.78
- Epithelial log2(TPM+1): 0.27
- Fold change: 1.50
- Status: Upregulated
High-confidence drugs
- Nilotinib — inh 93.8% · KISS 44.25
- Dasatinib — inh 100.0% · KISS 42.28
- Cabozantinib — inh 91.6% · KISS 36.34
Selectivity landscape vs inhibition on EPHA5
Each point is one of the 92 approved drugs; color = inhibition % on EPHA5.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…